Pargeverine

DB15783InvestigationalSmall molecule

Pargeverine: Overview.

Mechanism: Pharmacologically active on Voltage-dependent L-type calcium channel
Curator reviewed
Formula / weight: C₂₁H₂₃NO₃ · 337.419 g/mol (avg)
Code names: BE 50

Resolves to

Compound

Clinical / RWD

Structure

InChIKeyQNPHCSSJLHAKSA-UHFFFAOYSA-NSMILESCN(C)CCOC(=O)C(OCC#C)(C1=CC=CC=C1)C1=CC=CC=C1

What you can answer from here — as of August 30, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Structured indicationCondition, population, route and combination as fields, not prose

2Marketed productsAcross 1 country and 2 labellers

1+ReferenceStructured and connected to the statements they support

Which other approved drugs treat the same conditions as Pargeverine, and which companies have late-stage candidates in those indications?

Create a free account or log in to explore the full data card.